Current Pharmaceutical Research
Not a member yet
40 research outputs found
Sort by
Microsponge Drug Delivery Systems: Advancing Methotrexate Delivery for Rheumatoid Arthritis Management
No full textAn estimated 23 million individuals worldwide suffer with rheumatoid arthritis, a debilitating inflammatory illness with a prevalence incidence of 0.5–1%. This chronic illness mostly affects synovial joints, causing inflammation, joint degeneration, and bone erosion. Patients suffer from a very low quality of life, and the condition has a significant socioeconomic impact. The pathophysiology of RA is caused by a complicated interaction between genetic and environmental variables that disrupt the control of the immune system. TNF-α, IL-6, and IL-1β are important inflammatory mediators that cause bone resorption and joint degeneration as the illness progresses. Microsponge drug delivery systems have been developed as a promising strategy to improve the therapeutic efficacy of methotrexate, which is a cornerstone in RA treatment. These systems offer controlled release, improved bioavailability, and targeted delivery to inflamed joints while minimizing systemic toxicity. Microsponge drug delivery systems can be formulated as topical gels, creams, patches, or injectable hydrogels, which allows for a variety of administration routes. Microsponge drug delivery systems are known for offering benefits of delivering methotrexate drugs by sustaining its release, providing reduced dosing, stability in the drug itself, and causing less side effect. Some challenges of microsponge drug delivery systems include a complicated manufacturing process, scalability issues, and regulatory problems that hamper its application in the clinic. In order to prove the safety and effectiveness of microsponge drug delivery systems, future research will concentrate on refining their composition, developing scalable production methods, and conducting extensive clinical studies. Innovation will keep developing, and by enhancing patient adherence, therapeutic results, and the quality of life for patients suffering from rheumatoid arthritis, microsponge drug delivery systems have the potential to completely transform the way this chronic illness is treated
Importance of In-Process Quality Control for Product Safety and Integrity in Pharmaceutical Packaging
No full textIn-process quality control (IPQC) is a crucial aspect of pharmaceutical industries, ensuring accurate packaging processes and high-quality final products. It involves a comprehensive approach, including visual inspection of packaging materials and finished products, weighing and volume checks, sealing integrity assessment, accurate labeling, and monitoring of packaging line parameters. The process also scrutinizes the legibility and accuracy of printed packaging information, reviews batch records for adherence to standard procedures and good manufacturing practices, monitors tamper-evident features and environmental conditions, and collects random samples for testing. All IPQC activities are thoroughly documented. The collected data is managed and analyzed for trend identification, issue resolution, and continuous process improvement. Effective IPQC implementation reduces the risk of defects and regulatory non-compliance, ensuring product safety, and efficacy, and maintaining the company\u27s reputation
Innovative Nasal Drug Delivery Systems for Effective Brain Targeting and Blood-Brain Barrier Overcoming
No full textCentral nervous system (CNS) disorders remain among the most challenging conditions to treat due to the restrictive nature of the blood-brain barrier (BBB), which significantly limits the delivery of therapeutic agents to the brain. Traditional systemic drug delivery methods often result in low brain bioavailability and increased systemic side effects. In recent years, intranasal drug delivery has gained attention as a non-invasive and efficient route for targeting the brain, bypassing the BBB and providing faster therapeutic action. Advancements in nasal delivery technologies—such as breath-powered devices, magnetophoretic systems, iontophoresis, and nanocarrier-based formulations—have shown promising results in enhancing drug retention in the brain while minimizing peripheral exposure. These methods support the delivery of a wide range of therapeutic agents, including small molecules, peptides, proteins, stem cells, and genetic material, making them suitable for the treatment of neurodegenerative diseases, psychiatric disorders, brain tumors, and other CNS conditions. The evolving field of nasal drug delivery offers significant potential to revolutionize CNS therapeutics by improving treatment efficacy, patient compliance, and safety. Continued research and clinical validation will further establish intranasal delivery as a cornerstone in the management of complex brain disorders
Duvyzat (Givinostat) in Duchenne Muscular Dystrophy: Mechanisms, Clinical Impact, and Future Directions
No full textDuchenne Muscular Dystrophy (DMD) is a chronic, progressive neuromuscular disorder characterized by muscle degeneration and weakness due to mutations in the dystrophin gene. Although there is no cure, emerging therapies such as histone deacetylase (HDAC) inhibitors offer promising avenues to slow disease progression. Duvyzat (givinostat), an orally active HDAC inhibitor, has recently received FDA approval following results from the Phase 3 EPIDYS trial, which demonstrated a statistically significant improvement in motor function. Patients treated with Duvyzat showed a 1.25-second faster performance on the four-stair climb (4SC) test compared to placebo, and a 1.91-point higher North Star Ambulatory Assessment (NSAA) score over 72 weeks. Duvyzat was also associated with reduced muscle fat infiltration on MRI. This review discusses the mechanism of HDAC inhibition, clinical evidence supporting Duvyzat\u27s efficacy, its safety profile, and implications for the future of DMD treatment. Continued research is essential to explore long-term outcomes and synergistic potential with gene-targeted therapies
Rutin Nanoparticles: Pioneering New Frontier skincare
No full textt
Dermatological issues, spanning from common inflammatory conditions to skin aging and cancers, present significant challenges for effective treatment. The application of topical medications provides a promising method to specifically target skin problems while reducing systemic side effects. Rutin, a naturally occurring flavonoid recognized for its strong antioxidant, anti-inflammatory, and healing properties, presents considerable therapeutic potential for various dermatological applications. However, its limited ability to penetrate the skin and low bioavailability hinder its clinical effectiveness. Nanotechnology provides a practical solution to overcome these challenges by encapsulating Rutin in nanoparticles. This review examines the potential of Rutin-loaded nanoparticles as innovative surface modification techniques for skin-related uses. We explore the benefits of Rutin for skin health, the advantages of nanoparticle-delivery systems that are based on collaboration, alongside the joint effects of integration Rutin employing nanotechnology to improve local effectiveness. In addition, we investigate the different types of nanoparticles suitable for Rutinencapsulation, their techniques for enhancing drug delivery, and the promising preclinical and recent clinical information supporting the use of Rutin-loaded nanoparticles in tackling skin ailments. In the end, we explore the challenges and potential avenues for transforming this innovative approach into effective clinical topical therapies.
Nanostructured Lipid Carriers in Pulmonary Drug Delivery: Progress and Prospects
No full textThe potential of nanostructured lipid carriers to improve drug solubility, stability, and controlled release has made them a viable approach for pulmonary drug administration. Combining liquid and solid lipids, these carriers provide distinct benefits over conventional drug delivery methods, including enhanced bioavailability, less systemic adverse effects, and the capacity to encapsulate both hydrophilic and hydrophobic medications. In addition to delivering biologics, macromolecules, and cancer treatments, nanostructured lipid carriers may find use in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease, and pulmonary infections. Notwithstanding their benefits, there are still issues with manufacturing scaling up, getting beyond biological obstacles such mucociliary clearance, and handling safety and regulatory issues. More individualized, targeted care is becoming possible because to recent advancements in the design of nanostructured lipid carriers, such as smart delivery technologies and stimuli-responsive systems. This study emphasizes the potential of nanostructured lipid carriers to transform the treatment of respiratory disorders and enhance patient outcomes by highlighting their present advancements, difficulties, and future opportunities in pulmonary medication delivery
Hydrogel Nanostructures for Targeted Drug Delivery in Inflammatory Diseases: A Comprehensive Review
No full textIn the treatment of inflammatory illnesses, hydrogel nanostructures have shown themselves to be a flexible and promising substrate for targeted drug delivery. The biocompatibility, biodegradability, and controlled, localised drug release capabilities of these systems are highly regarded because they minimise systemic adverse effects and improve therapeutic efficacy. Systems based on hydrogel may be made to react to environmental cues like pH, temperature, or enzymatic activity that are frequently present in inflammatory tissues. Treatment results are improved by this responsiveness, which enables precise medication release at the location of inflammation. Targeting ligands, including peptides or antibodies, are added to improve the efficiency and specificity of medication delivery. By selectively binding to markers produced in inflammatory tissues, these ligands allow hydrogel nanostructures to improve medication accumulation at the intended region while minimising off-target effects. These developments might have a significant impact on diseases including psoriasis, inflammatory bowel illness, and rheumatoid arthritis. Clinical translation is nevertheless hampered by issues including stability, consistent biocompatibility, and manufacturing scalability, despite their potential. These restrictions should be solved by upcoming developments including combination medicines, stimuli-responsive hydrogels, and personalised medicine strategies. By providing more accurate control over medication distribution, these tactics may allow for patient-specific therapies and enhance overall results. A potential strategy for creating patient-centered, long-lasting, and efficient treatments for chronic inflammatory illnesses is the use of hydrogel nanostructures. These systems have the potential to revolutionise the treatment of a variety of inflammatory diseases by tackling present issues and utilising creative design techniques
Overview of the Vital Role of Vitamin D: Functions, Deficiency Syndromes, and Impact Throughout Life
No full textThe recent study provides a comprehensive overview of vitamin D, emphasizing its biological roles, sources, and health implications. Vitamin D, a fat-soluble prohormone, is essential for bone health, immune function, mental well-being, reproductive health, and the prevention of chronic diseases. Discovered in the early 20th century due to the anti-rachitic effects of cod liver oil, vitamin D includes two main inactive precursors: vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Vitamin D3 is endogenously synthesized in the skin through ultraviolet B (UVB) radiation (290–320 nm), while vitamin D2 originates from plants and is obtained through dietary intake. The synthesis and activation of vitamin D are influenced by factors such as UVB exposure, with excessive exposure leading to the formation of inactive metabolites like tachysterol and lumisterol. This overview underscores the critical importance of maintaining adequate vitamin D levels for optimal health outcomes
Neuroprotective Effects of Seaweeds in Alzheimer\u27s Disease: A Review
No full textAlzheimer\u27s disease (AD) is anprogressive neurodegenerative disorder with symptoms of progressive cognitive decline, including memory loss.The rapid worldwide increase in prevalence of AD highlights a high unmet need for novel AD therapies beyond symptom management. Current pharmacologic interventions, such as cholinesterase inhibitors and NMDA receptor antagonists, provide a marginal benefit in ameliorating disease progression. Thus, we look to onboard alternative ocean-derived bioactive constituents as therapeutics.Some of the bioactive compounds present in brown algae (seaweeds), in particular, such as fucoidan, phlorotannins, and alginate, demonstrate neuroprotective action by inhibition of oxidative stress and neuroinflammation in addition to the amyloid-induced plaques (the major hallmarks of AD pathology).Antioxidant and anti-inflammatory polysaccharides from green and red algae may also play a role in the preservation of cognitive functions due to their content in species. Preclinical trials in the past have shown that these compounds can be useful for neuroprotection and even disease modification.While this is promising, further research and clinical trials are needed to demonstrate the impact on AD treatment with seaweed-derived compounds. Placing a bet on the new advances of science, marine bioresources, while not neglecting the progress noticed these days in enhancing the lives of AD creatures
Targeting Metabolic Liver Disorders with Sodium Orthovanadate: A Novel Therapeutic Strategy
No full textNon-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) are major hepatic disorders characterized by lipid accumulation, oxidative stress, and inflammation, yet they differ fundamentally in aetiology. While NAFLD is primarily driven by insulin resistance and metabolic syndrome, AFLD arises from chronic alcohol consumption and the hepatotoxic effects of its metabolites. Current therapeutic approaches for both conditions are limited, often relying on lifestyle modifications or nonspecific pharmacological agents, with suboptimal outcomes. Sodium orthovanadate (SOV), an inorganic vanadium compound, has emerged as a novel candidate due to its multifaceted pharmacological profile. Acting as an insulin mimetic, SOV enhances insulin signalling and glucose uptake, while also exerting potent antioxidant and anti-inflammatory effects. These properties make it uniquely suited to address both metabolic and alcohol-related liver dysfunction. Preclinical studies have demonstrated SOV’s ability to reduce hepatic steatosis, normalize lipid profiles, improve mitochondrial function, and suppress inflammatory cytokines. Notably, its mechanism of action in NAFLD primarily involves modulation of glucose and lipid metabolism via PI3K/Akt pathways, whereas in AFLD, it acts by attenuating oxidative damage and downregulating NF-κB-mediated inflammation. Despite these promising outcomes, clinical translation is constrained by concerns regarding long-term toxicity. Nevertheless, SOV holds significant potential as a dual-purpose therapeutic agent targeting the complex pathophysiology of fatty liver diseases